Q2 2026 saw 5% sales growth to $16.6B, led by oncology and animal health, but reported a GAAP net loss due to a $2.31/share charge for the Terns acquisition. Full-year sales guidance was raised to $66.3–$67.3B, with non-GAAP EPS expected at $2.66–$2.76.Original document: Merck & Company, Inc. [MRK…
Q2 2026 saw 5% sales growth to $16.6B, led by oncology and animal health, but reported a GAAP net loss due to a $2.31/share charge for the Terns acquisition. Full-year sales guidance was raised to $66.3–$67.3B, with non-GAAP EPS expected at $2.66–$2.76.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
